Follow Us
© 2026 Arizent. All rights reserved.
For reprint and licensing requests for this article, click here.
Collaboration between employers, brokers and third-party administrators will be essential to developing customized, cost-effective and employee-friendly solutions.
As GLP-1 spending climbs, employers are asking whether the drugs deliver enough value. Better data could help them measure the payoff more accurately.
Employers are under pressure to keep benefits competitive while controlling costs, driving new scrutiny of PBMs, hospital prices and GLP-1 coverage for 2027.
To truly flip the script on metabolic disease, benefit leaders must build a cost-efficient, supportive plan for employees and their business.
Setting clear expectations and equipping health plan members with usable information will build trust and eliminate employee friction in the face of change.
